An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2018
Price : $35 *
At a glance
- Drugs Lonafarnib (Primary) ; Pravastatin; Zoledronic acid
- Indications Progeria
- Focus Therapeutic Use
- Acronyms ProLon2
- 16 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2020.
- 16 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2019.
- 24 Apr 2018 Results of a pooled analysis (ProLon1 and ProLon2; n=63) trials assessing the association of lonafarnib with mortality rate versus no treatment (n=103), published in the JAMA: the Journal of the American Medical Association